BioSpace News Archive

The Transformation Into a Company Focused on Clinical Development of Pharmaceuticals has now been Completed and Medivir Gives a Project Update

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the transformation to focus the company’s internal resources on its clinical development projects has now been completed.

December 14, 2018
·
4 min read
Pharm Country

12-Month Results from Study of NeoTract’s UroLift® System for BPH in Men with an Obstructive Median Lobe Published in Prostate Cancer and Prostatic Diseases

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the publication of 12-month data from the multi-center prospective MedLift™ Study of the UroLift® System treatment for Benign Prostatic Hyperplasia (BPH) in patients with an obstructive median lobe.

December 14, 2018
·
5 min read
Genetown

Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer

Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented clinical data from its ongoing Phase I/II study of TRX518 in combination with gemcitabine, KeytrudaÒ (pembrolizumab), or OpdivoÒ (nivolumab) in patients with advanced solid tumors at the European Society for Molecular Oncology (ESMO) Immuno-Oncology Congress 2018.

December 14, 2018
·
11 min read
Business

Sun Nuclear Releases 1028 XP Continuous Radon Monitor

Sun Nuclear Corporation, a leading provider of Continuous Radon Monitors (CRMs) for commercial and residential purposes, today announced release of the 1028™ XP Continuous Radon Monitor.

December 14, 2018
·
2 min read
Pharm Country

Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients

he Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental New Drug Application (sNDA) for XARELTO® (rivaroxaban) to the U.S. Food and Drug Administration (FDA) for the prevention of venous thromboembolism (VTE), or blood clots, in medically ill patients.

December 14, 2018
·
14 min read
BioForest

National Report: Arizona Ranks 17th in Protecting Kids from Tobacco

Arizona ranks 17th nationwide in funding programs that prevent kids from using tobacco and help smokers quit, according to a report released by leading public health groups.

December 14, 2018
·
4 min read
BioForest

National Report: Alabama Ranks 38th in Protecting Kids from Tobacco

Alabama ranks 38th nationwide in funding programs that prevent kids from using tobacco and help smokers quit, according to a report released by leading public health groups.

December 14, 2018
·
3 min read
BioForest

National Report: Kentucky Ranks 35th in Protecting Kids from Tobacco

Kentucky ranks 35th nationwide in funding programs that prevent kids from using tobacco and help smokers quit, according to a report released by leading public health groups.

December 14, 2018
·
4 min read
BioForest

National Report: Iowa Ranks 25th in Protecting Kids from Tobacco

Iowa ranks 25th nationwide in funding programs that prevent kids from using tobacco and help smokers quit, according to a report released by leading public health groups.

December 14, 2018
·
3 min read
BioForest

National Report: Mississippi Ranks 21st in Protecting Kids from Tobacco

Mississippi ranks 21st nationwide in funding programs that prevent kids from using tobacco and help smokers quit, according to a report released by leading public health groups.

December 14, 2018
·
4 min read